{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:00:59Z","timestamp":1794841259535,"version":"4.9.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.critrevonc.2024.104462","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T05:34:28Z","timestamp":1722576868000},"page":"104462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis"],"prefix":"10.1016","volume":"202","author":[{"given":"Gabrielle J.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2024.104462_bib1","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/imt-2018-0149","article-title":"Immunotherapy plus surgery\/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis","volume":"11","author":"Amaral","year":"2019","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000333","article-title":"Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104462_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E","article-title":"Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival","volume":"42","author":"Amer","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104462_bib5","unstructured":"Australia, M.I., Anti-PD-1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) . 2017."},{"issue":"no pagination","key":"10.1016\/j.critrevonc.2024.104462_bib6","article-title":"Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: a retrospective monocentric toxicity analysis","volume":"39","author":"Bodensohn","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104462_bib7","unstructured":"Borman, I. Digitizeit. Digitizeit 1999; Available from: \u3008https:\/\/www.digitizeit.xyz\/\/eula.html\u3009."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104462_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081857","article-title":"Ipilimumab and stereotactic radiosurgery with cyberknife system in melanoma brain metastases: a retrospective monoinstitutional experience","volume":"13","author":"Borzillo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104462_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2020.04.028","article-title":"Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: a retrospective study of safety and efficacy","volume":"135","author":"Carron","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104462_bib10","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1007\/s12094-022-02838-3","article-title":"Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence","volume":"24","author":"de Castro","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104462_bib11","unstructured":"Cochrane, Cochrane Handbook for Systematic Review of Interventions version 6.3, T.J.C.J. Higgins J, Cumptson M, Li T, Page M, Welch V, Editor. 2022."},{"key":"10.1016\/j.critrevonc.2024.104462_bib12","unstructured":"Cochrane Collaboration, Review Manager (RevMan) [Computer program]. Version 5.3. 2014, The Nordic Cochrane Centre.: Copenhagen."},{"key":"10.1016\/j.critrevonc.2024.104462_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113287","article-title":"Stereotactic radiosurgery and anti-PD-1+ CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases","volume":"192","author":"Dohm","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"2 Supplement 1","key":"10.1016\/j.critrevonc.2024.104462_bib14","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1016\/j.ijrobp.2016.06.882","article-title":"Clinical outcomes of combined BRAF and MEK inhibition with stereotactic radiation for BRAF mutant melanoma brain metastases","volume":"96","author":"Echevarria","year":"2016","journal-title":"Int. J. Radiat. Oncol."},{"issue":"9829","key":"10.1016\/j.critrevonc.2024.104462_bib15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104462_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104462_bib17","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1002\/cam4.3021","article-title":"Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study","volume":"9","author":"Gatterbauer","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2024.104462_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2017.07.017","article-title":"Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery","volume":"84","author":"Gaudy-Marqueste","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104462_bib20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/bjc.2016.318","article-title":"RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt","volume":"115","author":"Gupta","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104462_bib21","unstructured":"Higgins J.P., G.Se Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, ed. G.S. Higgins JP. 2011: The Cochrane Collaboration."},{"key":"10.1016\/j.critrevonc.2024.104462_bib22","doi-asserted-by":"crossref","unstructured":"Higgins, P.T.A., D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic J.;Schulz, K.F.; weeks, L.; Sterne, J.A.C.;, The Cochrane Collaboration's tool for assessing risk of bias in randomsied trials. British Medical Journal, 2011. 343: p. d5928.","DOI":"10.1136\/bmj.d5928"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104462_bib23","doi-asserted-by":"crossref","DOI":"10.3171\/2014.12.FOCUS14698","article-title":"Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series","volume":"38","author":"Jones","year":"2015","journal-title":"Neurosurg. Focus"},{"issue":"3 Supplement","key":"10.1016\/j.critrevonc.2024.104462_bib24","article-title":"Real world outcomes of melanoma brain metastases treated with immunotherapy with or without stereotactic radiosurgery","volume":"114","author":"Kleber","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3 Supplement","key":"10.1016\/j.critrevonc.2024.104462_bib25","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/j.ijrobp.2021.07.1542","article-title":"Concurrent vs. Sequential Stereotactic Radiosurgery and Immune Checkpoint Inhibition in Melanoma Brain Metastases: An International Cooperative Group Study","volume":"111","author":"Lehrer","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104462_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000044","article-title":"Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib","volume":"24","author":"Liebner","year":"2014","journal-title":"Melanoma Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104462_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/neuros\/nyy203","article-title":"BRAF V600 Mutation and BRAF Kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study","volume":"84","author":"Mastorakos","year":"2019","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104462_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0266462305050154","article-title":"Meta-analysis when only the median survival times are known: a comparison with individual patient data results","volume":"21","author":"Michiels","year":"2005","journal-title":"Int. J. Technol. Assess. Health care"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","article-title":"Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity","volume":"7","author":"Minniti","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104462_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003730","article-title":"Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases","volume":"9","author":"Minniti","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104462_bib33","first-page":"3427","article-title":"Patterned distribution of metastases from malignant melanoma in humans","volume":"43","author":"de la Monte","year":"1983","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cam4.3716","article-title":"Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases","volume":"10","author":"Moyers","year":"2021","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104462_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000385","article-title":"Long-term overall survival and predictors in anti-PD-1-naive Melanoma patients with brain metastases treated with immune checkpoint inhibitors in the real-world setting: a multicohort study","volume":"44","author":"Naik","year":"2021","journal-title":"J. Immunother."},{"issue":"2 Supplement 1","key":"10.1016\/j.critrevonc.2024.104462_bib36","article-title":"Effectiveness and safety of combined cranial stereotactic radiation and anti-PD-1 therapy for melanoma brain metastases","volume":"99","author":"Neto","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104462_bib37","unstructured":"Network, N.C.C. Melanoma: Cutaneous (Version 3.2022). 2022 September 12 2023]; Available from: \u3008https:\/\/www.nccn.org\/professionals\/physicians_gls\/pdf\/cutaneous_melanoma.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104462_bib38","doi-asserted-by":"crossref","unstructured":"Orduno, N.M., et al., Observational study assessing survival outcomes in advanced melanoma patients with brain metastases treated with immunotherapy with or without radiotherapy: Effect of radiotherapy sequence and modality. Clinical Cancer Research. Conference: AACR Special Conference on Radiation Science and Medicine. Virtual., 2021. 27(8 SUPPL).","DOI":"10.1158\/1557-3265.RADSCI21-PO-045"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000250","article-title":"Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res."},{"key":"10.1016\/j.critrevonc.2024.104462_bib41","unstructured":"Peterson, J., et al., The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute, 2011."},{"key":"10.1016\/j.critrevonc.2024.104462_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2018.12.023","article-title":"Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases","volume":"110","author":"Rauschenberg","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104462_bib43","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00066-018-1356-5","article-title":"Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters","volume":"194","author":"Schmidberger","year":"2018","journal-title":"Strahlenther. und Onkol."},{"issue":"2 SUPPL","key":"10.1016\/j.critrevonc.2024.104462_bib44","first-page":"120","article-title":"Effect of concomitant encephalic radiotherapy (RT) with anti- PD1 or targeted therapy in melanoma brain metastases (BM): a retrospective single institutional study","volume":"107","author":"Sergi","year":"2021","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2024.104462_bib45","doi-asserted-by":"crossref","unstructured":"Shoukat, S., et al., Outcome with stereotactic radiosurgery (SRS) and ipilimumab (ipi) for malignant melanoma brain metastases (mets). 2014, American Society of Clinical Oncology.","DOI":"10.1200\/jco.2014.32.15_suppl.9076"},{"issue":"Supplement 7","key":"10.1016\/j.critrevonc.2024.104462_bib46","doi-asserted-by":"crossref","first-page":"S930","DOI":"10.1016\/j.annonc.2022.07.960","article-title":"Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)","volume":"33","author":"Silva Almeida Ribeiro","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4780060104","article-title":"Confronting publication bias: a cohort design for meta-analysis","volume":"6","author":"Simes","year":"1987","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104462_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"6","author":"Skrepnik","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2024.104462_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2017.10.006","article-title":"Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy","volume":"313","author":"Stokes","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104462_bib50","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","article-title":"Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma","volume":"4","author":"Theurich","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2024.104462_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2478\/raon-2022-0032","article-title":"Radiation therapy for melanoma brain metastases: A systematic review","volume":"56","author":"Thompson","year":"2022","journal-title":"Radiology and Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-020-03663-w","article-title":"Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome","volume":"152","author":"Wegner","year":"2021","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104462_bib54","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3171\/2016.2.JNS1633","article-title":"BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases","volume":"126","author":"Xu","year":"2017","journal-title":"J. Neurosurg."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104462_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104462_bib56","doi-asserted-by":"crossref","unstructured":"Yamamoto, M., et al., Stereotactic radiosurgery for patients with 10 or more brain metastases, in Leksell Radiosurgery. 2019, Karger Publishers. p. 110-124.","DOI":"10.1159\/000493056"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104462_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CMR.0000000000000538","article-title":"Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study","volume":"29","author":"Zhang","year":"2019","journal-title":"Melanoma Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T20:13:14Z","timestamp":1725480794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":57,"alternative-id":["S1040842824002051"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104462","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104462"}}